Business Operations

Pharmaceuticals Business

i) Generic Drugs

We deliver economical, high-value-added generic drugs underpinned by reliable information provision capabilities.

To lessen the burden on patients and improve the financial management situation of the nation’s health insurance system, the Japanese government is promoting the use of generic drugs. To this end, a new utilization objective has been set that would raise the share of prescriptions for generic drugs to 80% or above no later than the end of September this year, and recently, the relevant parties of the government have been discussing the setting of new targets in preparation for this change. The Nippon Chemiphar Group thus is applying its integrated capabilities to the development, manufacture, and marketing of new drugs and generics. Ultimately, we are pursuing the development of those generics that reflect the needs of patients and healthcare professionals.

ii) Proprietary Products and Drug Discovery, Marketing Rights

We aim to add fresh dimensions to our distinctive proprietary products, and develop groundbreaking new drugs.

Aiming to open up potential in new therapeutic fields, Nippon Chemiphar currently is pursuing clinical research on our three long-available proprietary products: alkalization therapeutic drug Uralyt-U, analgesic and anti-inflammatory drug Soleton, and hypertension therapeutic drug Calvan. We are confident that this will lead to considerable market expansion for the products.
In February 2019, we acquired marketing authorization for the PICOPREP compound oral intestinal cleansing agent from Ferring Pharmaceuticals Co., Ltd. and are already logging sales. Then in May, we concluded an agreement with Mylan EPD G.K. regarding the transfer of sales rights for Klaricid, a macrolide antibiotic agent. The agreement will allow the Company to manufacture and sell Klaricid and use related trademarks. The agreement strengthens our product portfolio and creates synergy with the generics business.
At the same time, we are continuing to aggressively pursue drug discovery themes that have the potential to lead to groundbreaking new drugs focused on our specialties of hyperuricemia and pain.

Diagnostics Business

From treatment to prevention.

Nippon Chemiphar provides measuring equipment and reagents used to fight allergies and lifestyle-related diseases, and markets these in-house developed products at home and abroad. We are currently developing a business based on technical collaboration with Chinese companies, as well as new and innovative products that will enable quick measurement from small blood samples.
-Read more

Healthcare Business

Expanding benefits.

The Nippon Chemiphar Group handles a diverse array of healthcare products, including nutrients, health foods, cosmetics, and various types of creams, classified as quasi-drugs because they contain a certain concentration of particular active ingredients.
Amid the rising needs surrounding consumer selfmedication, we are leveraging trustworthiness and the development expertise we have gained as a pharmaceutical product manufacturer to make a difference in people’s lives and provide a high level of added value.

Related Information